Investigation of the Pharmacokinetic Profile of Nanoemulsion CBD
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The goal of the current study is to evaluate the bioavaibiltiy of nanoemulsion CBD in normal
healthy Individuals. This is an open cross-over design study in healthy individuals to assess
the safety and pharmacokinetic (PK) effects of nanoemulsion cannabidiol.